This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia	B cell CLL lymphoma 6 (BCL6)	<p>Studies in cell culture and mice suggest inhibiting BCL6 could help treat CML. In human CML cell lines, Gleevec imatinib plus a peptide inhibitor of BCL6 increased cell death compared with Gleevec alone. In mice with CML, injection of a BCL6 peptide inhibitor improved survival compared with injection of vehicle control. Next steps include developing more BCL6 inhibitors. Novartis AG's tyrosine kinase inhibitors Tasigna nilotinib and Gleevec imatinib are marketed to treat CML.</p> <p>SciBX 4(38); doi:10.1038/scibx.2011.1064 Published online Sept. 29, 2011</p>	Patent application filing in progress; licensing status undisclosed	<p>Hurtz, C. <i>et al. J. Exp. Med.</i>; published online Sept. 12, 2011; doi:10.1084/jem.20110304 Contact: Markus Müschen, University of California, San Francisco, Calif. e-mail: markus.muschen@ucsf.edu</p>